Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.

Diabetes Res Clin PractJul 13, 2026 (epub)
Clinical ResearchEndocrinologyCardiology

Bernardo F Spiazzi, Carolina P Zingano, Verônica Colpani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of tirzepatide on cardiovascular outcomes and mortality in 29,023 adults with type 2 diabetes or obesity. The study found that tirzepatide significantly reduced major adverse cardiovascular events (MACE) with an odds ratio of 0.87, indicating a beneficial effect on cardiovascular health in this population.

Key findings

  • Tirzepatide reduced MACE with an odds ratio of 0.87 (95% CI 0.79-0.94).
  • There was a 2.8% lower odds of MACE for every 1 mg increase in tirzepatide dose.
  • Tirzepatide was associated with a reduction in all-cause mortality (OR 0.84, 95% CI 0.75-0.93).

Why it matters

The findings suggest that tirzepatide may improve cardiovascular outcomes and reduce mortality in patients with type 2 diabetes or obesity, which is crucial given the high cardiovascular risk in these populations.

Source

PubMed · PMID 42442557

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.